The safety and efficacy of bevacizumab in the treatment of patients with recurrent or metastatic cervical cancer

Minion, Lindsey E.; Tewari, Krishnansu S.

doi:10.1080/14737140.2016.1246187

Cited by 21 publications

(18 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…VEGF signalling participates in several important physiologic processes (i.e., angiogenesis and blood pressure regulation) [3]. While blocking VEGF signalling may inhibit the progression of advanced CC, it can also initiate unintended effects because several other functional adjustments are achieved through VEGF signalling [27,28]. BEV is directly related to the development of hypertension, which is a recognized effect of anti-VEGF therapy [3].…”

Section: Discussionmentioning

confidence: 99%

Cisplatin plus paclitaxel chemotherapy with or without bevacizumab in postmenopausal women with previously untreated advanced cervical cancer: a retrospective study

Chu

Liu

et al. 2021

BMC Cancer

View full text Add to dashboard Cite

Background The aim of this study was to assess the survival outcomes of cisplatin-paclitaxel chemotherapy plus bevacizumab (CPB) versus cisplatin-paclitaxel chemotherapy alone (CPA) in postmenopausal women with previously untreated advanced cervical cancer (CC). Methods Consecutive postmenopausal women who experienced CPB or CPA were identified retrospectively from our medical centre during 2015–2019. Follow-up visits occurred 1 and 3 months after starting CPB or CPA. Afterwards, this assessment was conducted every 3 months for 1 year and then yearly thereafter. The primary endpoints were overall survival (OS) and progression-free survival (PFS); secondary endpoints were the frequency and severity of adverse events (AEs). Results Two hundred forty-six postmenopausal women were included (CPB, n = 124; CPA, n = 122). The median follow-up for the entire cohort was 24 months (range, 2–32). At the final follow-up, a significant difference was detected in terms of median OS (16.4 months [95% CI, 15.3–17.1] for CPB vs. 12.3 months [95% CI, 10.2–13.5] for CPA; hazard ratio (HR) 0.69, 95% CI, 0.49–0.99; p = 0.001), and the median PFS was longer in the CPB group than in the CPA group (9.2 months [95% CI, 8.3–10.7] vs. 7.9 months (95% CI, 6.1–8.6) (HR 0.62, 95% CI, 0.47–0.82; p < 0.001). There were significant differences in the number of AEs between the groups (hypertension grade ≥ 2 [p < 0.001], neutropenia grade ≥ 4 [p < 0.001], and thrombosis/embolism grade ≥ 3 [p = 0.030]). Conclusions Among postmenopausal women with previously untreated advanced CC, those who received CPB experienced superior survival benefits compared to those who received CPA. The safety profile for CPB was controllable despite the long duration of CPB use.

show abstract

Section: Discussionmentioning

confidence: 99%

Cisplatin plus paclitaxel chemotherapy with or without bevacizumab in postmenopausal women with previously untreated advanced cervical cancer: a retrospective study

Chu

Liu

et al. 2021

BMC Cancer

View full text Add to dashboard Cite

show abstract

“…70 Vaccines are also being used to treat recurrent, persistent cervical cancer by modulating T-cell immunity and activating the immune system to destroy cells that display tumor-associated antigens. 71 A Listeria-based vaccine, ADXS11-001, demonstrated an 11% response rate in a phase 2 investigation among patients with recurrent or refractory cervical cancer. 72 OPC Treatment for OPC is the same regardless of HPV status or p16 positivity, despite improved outcomes in HPVpositive OPC.…”

Section: Cervical Cancermentioning

confidence: 99%

Human papillomavirus in cervical cancer and oropharyngeal cancer: One cause, two diseases

Berman

Schiller

2017

Cancer

321

290

View full text Add to dashboard Cite

Human papillomavirus (HPV) causes greater than 5% of cancers worldwide, including all cervical cancers and an alarmingly increasing proportion of oropharyngeal cancers (OPCs). Despite markedly reduced cervical cancer incidence in industrialized nations with organized screening programs, cervical cancer remains the second most common cause of death from cancer in women worldwide, as developing countries lack resources for universal, high-quality screening. In the United States, HPV-related OPC is only 1 of 5 cancers with a rising incidence since 1975 and now has taken over the cervix as the most common site of HPV-related cancer. Similar trends follow throughout North America and Europe. The need for early detection and prevention is paramount. Despite the common etiologic role of HPV in the development of cervical cancer and HPV-associated OPC, great disparity exists between incidence, screening modalities (or lack thereof), treatment, and prevention in these 2 very distinct cohorts. These differences in cervical cancer and HPV-associated OPC and their impact are discussed here. Cancer 2017;123:2219-2229. © 2017 American Cancer Society.

show abstract

“…16 Bevacizumab inhibits nitric oxide synthase, which leads to nonhematological adverse effects such as hypertension. 7 Hematological adverse effects were attributed to treatment-naive women. 3 The other nonhematological adverse effects, that is, gastrointestinal fistula, were due to recurrence status 10,16 of women (73%; 211/288).…”

Section: Discussionmentioning

confidence: 99%

“…5 Bevacizumab is a monoclonal type antibody that inhibits the vascular endothelial growth factor, which is the key parameter of tumor angiogenesis. 7 Paclitaxel and topotecan or paclitaxel and cisplatin is approved by the United States Food and Drug Administration for advanced cervical cancer. 8 A randomized trial reported that the addition of bevacizumab to present chemotherapy in recurrent, persistent, or metastatic cervical cancer women improved overall survival but has emergent adverse effects such as gastrointestinal fistula, hypertension, and thromboembolism.…”

Section: Introductionmentioning

confidence: 99%

Paclitaxel, Carboplatin, and Bevacizumab in Advanced Cervical Cancer: A Treatment Response and Safety Analysis

et al. 2020

View full text Add to dashboard Cite

Background: Trials reported there are beneficial effects of the addition of bevacizumab to chemotherapy in advanced cervical cancer but might have adverse effects. The purposes of the study were to evaluate the treatment response and safety of the addition of bevacizumab to paclitaxel plus carboplatin in advanced cervical cancer women. Methods: Data on treatment response, adverse effects, and overall survival of women who received paclitaxel plus carboplatin every 3 weeks (ACT cohort, n = 161) or paclitaxel, carboplatin, and bevacizumab every 3 weeks (PCB cohort, n = 127) until disease progression or severe adverse events were collected and analyzed. Results: The treatment response of paclitaxel plus carboplatin increased on addition of bevacizumab ( P = .037). Neutropenia (grade ≥3, P = .001), leukopenia (grade 4, P = .041), anemia (grade ≥3, P = .031), hypertension (grade ≥2, P = .002), and gastrointestinal fistula (grade ≥2, P = 0.006) are reported in the PCB cohort. Women of ACT and PCB cohorts reported an overall survival of 20.11 ± 3.15 months and 24.52 ± 4.05 months, respectively. Conclusions: Addition of bevacizumab increases the treatment response of paclitaxel and carboplatin chemotherapy and overall survival of women with advanced cervical cancers, but it is not well tolerated.

show abstract

The safety and efficacy of bevacizumab in the treatment of patients with recurrent or metastatic cervical cancer

Cited by 21 publications

References 42 publications

Cisplatin plus paclitaxel chemotherapy with or without bevacizumab in postmenopausal women with previously untreated advanced cervical cancer: a retrospective study

Cisplatin plus paclitaxel chemotherapy with or without bevacizumab in postmenopausal women with previously untreated advanced cervical cancer: a retrospective study

Human papillomavirus in cervical cancer and oropharyngeal cancer: One cause, two diseases

Paclitaxel, Carboplatin, and Bevacizumab in Advanced Cervical Cancer: A Treatment Response and Safety Analysis

Contact Info

Product

Resources

About